Polymer-Based, Paclitaxel-Eluting TAXUS Liberté Stent in De Novo LesionsThe Pivotal TAXUS ATLAS Trial
Mark A. Turco, MD*,*,
John A. Ormiston, MBChB ,
Jeffrey J. Popma, MD ,
Lazar Mandinov, MD ,
Charles D. O’Shaughnessy, MD||,
Tift Mann, MD¶,
Thomas F. McGarry, MD#,
Chiung-Jen Wu, MD**,
Charles Chan, MD,
Mark W.I. Webster, MBChB,
Jack J. Hall, MD,
Gregory J. Mishkel, MD||||,
Louis A. Cannon, MD¶¶,
Donald S. Baim, MD and
Joerg Koglin, MD
* Center for Cardiac & Vascular Research, Washington Adventist Hospital, Takoma Park, Maryland
Mercy Angiography Unit, Mercy Hospital, Auckland, New Zealand
Department of Internal Medicine (Cardiovascular Division), Brigham and Women’s Hospital, Boston, Massachusetts
Boston Scientific Corporation, Marlborough, Massachusetts
|| Elyria Memorial Hospital, Elyria, Ohio
¶ Wake Heart Associates, Wake Medical Center, Raleigh, North Carolina
# Oklahoma Foundation for Cardiovascular Research, Oklahoma Heart Hospital, Oklahoma City, Oklahoma
** Cardiology Section, Chang-Gung Memorial Hospital, Kaohsiung, Taiwan
National Heart Centre, Singapore, Singapore
Cardiac Investigations Unit, Auckland City Hospital, Auckland, New Zealand
The Heart Center, St. Vincent’s Hospital, Indianapolis, Indiana
|||| Prairie Heart Institute, St. John’s Hospital, Springfield, Illinois
¶¶ Cardiac & Vascular Research Center, Northern Michigan Hospital, Petoskey, Michigan.
View larger version (26K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 2 Study Flow and Control Group Selection
(A) The TAXUS ATLAS study flow. (B) Selection of the TAXUS Express control group. Patients from the TAXUS IV and V trials were selected based on entry criteria for the TAXUS ATLAS trial. All 662 TAXUS Express patients from the TAXUS IV trial were included. Of the 577 TAXUS Express patients in the TAXUS V trial, 248 were excluded for reference vessel diameter (RVD) <2.5 mm, lesion length >28 mm, or >1 study stent planned for implantation. *Based on visual estimate. Angio = angiography; F/U = follow-up; ITT = intention-to-treat population; IVUS = intravascular ultrasound; PP = per-protocol population.
|
|
View larger version (26K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 4 Cumulative Freedom-From-Event Rates
(A) Major adverse cardiac events (MACE) or (B) target vessel revascularization (TVR). Data shown are for the per-protocol population (n = 1,845).
|
|
View larger version (26K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 5 Angiographic Measures
(A) In-stent or in-lesion minimum lumen diameter (MLD) measures over time. Data from the intention-to-treat population (n = 1,862) at pre- and post-procedure, and from the angiographic subset (n = 1,247) at 9 months. (B) Cumulative frequency distribution curves for in-stent late loss as determined by quantitative coronary angiography in the angiographic subset (n = 1,247).
|
|
|
